Drug discovery firm creates 150 new jobs at Alderley Park

Drug discovery and non-clinical solutions firm, Sygnature Discover, has announced plans to expand its presence at Alderley Park, creating 150 jobs at the Cheshire science park.

The firm’s methodology relies on the use of integrated interdisciplinary teams, and the new roles will add biology and chemistry expertise to existing DMPK and Translational Oncology specialists.

The 150 new jobs will add to the drug discovery firm’s existing 425 staff based in Nottingham and turn the Alderley Park hub into a second integrated site.

Dr Simon Hirst, CEO & Founder, Sygnature Discovery, said:

This is a tremendous opportunity for Sygnature. Increasing demand for our services has driven our decision to expand, and Alderley Park, with its well-earned reputation here and internationally, provides the ideal home for our new integrated site.

“With exceptional facilities tailored to our needs, an incredible set of neighbours operating on-site, and a phenomenal talent pool for us to draw from, we are set for a bright future at Alderley Park.”

Dr Kath Mackay, Managing Director, Bruntwood SciTech – Alderley Park, said:

UK life sciences has a once-in-a-generation opportunity to establish itself as a world leader, and businesses like Sygnature Discovery will be at the forefront of that push.

“Sygnature’s expansion will enable it to better collaborate within the ecosystem of companies already based here, in turn driving innovation, and make it more attractive to the talent on offer on its doorstep. We’re proud to be playing our part in helping Sygnature deliver vital drug discovery research that will have long-lasting benefits for patients.”